title: Secondary haematological neoplasm after treatment of adult acute lymphoblastic leukemia: analysis of 1170 adult ALL patients enrolled in the GIMEMA trials. Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto.
abstract: Between 1983 and 1994 the incidence of secondary haematological neoplasms (SHM) was evaluated in 1170 new cases of ALL enrolled in the GIMEMA trials. Of the 942 patients who achieved complete remission (CR); seven developed a SHM: four AMLs and three NHLs. The median latency from onset of ALL and of secondary haematological neoplasm was 69 months for AML and 61 months for NHL. Three out of four patients with secondary AML were unresponsive to the new chemotherapy and died, whereas the fourth patient achieved a new CR. Among the three NHL cases, two patients are presently alive in CR, whereas the third patient was refractory to chemotherapy and died. The relative risk of haematological malignancy among the GIMEMA trials population, as compared to that of the Italian Cancer Registries, was 15.25-fold higher, and the actuarial estimated cumulative proportion of ALL patients with a secondary haematological neoplasm at 5 and 10 years were 0.59% and 3.63% respectively. The incidence of adult ALL who developed a SHM, although apparently lower than in the paediatric ALL series, was higher when compared to the normal population. The difference between paediatric and adult ALL is probably due to the lack of craniospinal radiotherapy and to the lower doses of epipodoxiphyllotoxins used in adult trials. The higher percentage of childhood ALL with a prolonged event-free survival could result in an increase of secondary neoplasms in these cases, which suggests that secondary haematological neoplasms in adult ALL patients are real, although rare, events.
authors.forename: L
authors.initials: L
authors.lastname: Pagano
authors.forename: L
authors.initials: L
authors.lastname: Annino
authors.forename: A
authors.initials: A
authors.lastname: Ferrari
authors.forename: A
authors.initials: A
authors.lastname: Camera
authors.forename: B
authors.initials: B
authors.lastname: Martino
authors.forename: M
authors.initials: M
authors.lastname: Montillo
authors.forename: M E
authors.initials: ME
authors.lastname: Tosti
authors.forename: A
authors.initials: A
authors.lastname: Mele
authors.forename: A
authors.initials: A
authors.lastname: Pulsoni
authors.forename: M L
authors.initials: ML
authors.lastname: Vegna
authors.forename: G
authors.initials: G
authors.lastname: Leone
authors.forename: F
authors.initials: F
authors.lastname: Mandelli
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D002648:Child; D002986:Clinical Trials as Topic; D019337:Hematologic Neoplasms / Q000209:etiology*; D006801:Humans; D008875:Middle Aged; D016609:Neoplasms, Second Primary / Q000139:chemically induced*; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy*; D012074:Remission Induction; D017211:Treatment Failure